Chair boosts stake at Tiziana Life Sciences (TLSA) with share buy

Rhea-AI Filing Summary

On September 5, 2025, Tiziana Life Sciences LTD reported that its Executive Chairman and Founder, Gabriele Cerrone, purchased 25,000 common shares at $1.60 per share. This transaction increased his total holding to 43,277,143 common shares, representing 36.28% of the company’s issued share capital. The move signals a larger personal stake by the company’s top insider, aligning his interests more closely with other shareholders.

Insights

Equity markets and governance analyst

Insider share purchase modestly increases the chair’s already large stake.

Tiziana Life Sciences LTD discloses that Executive Chairman and Founder Gabriele Cerrone bought 25,000 common shares at $1.60 per share. Following this transaction, his total holding is 43,277,143 common shares, equal to 36.28% of issued share capital.

The filing highlights a slight increase in an already significant ownership position rather than a transformative change. A large insider stake can align leadership with other shareholders, though it may also concentrate voting power.

The details are limited to this specific trade and resulting ownership level as of September 5, 2025. Subsequent filings may provide additional context on any further transactions or changes in ownership.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

September 2025

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F o

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 5, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 25,000 common shares at $1.60 per share, bringing his total holding to 43,277,143 common shares, which is 36.28% of issued share capital.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: September 5, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated September 5, 2025

3

FAQ

What insider transaction did Tiziana Life Sciences (TLSA) report in this Form 6-K?

The company reported that Executive Chairman and Founder Gabriele Cerrone purchased 25,000 common shares of Tiziana Life Sciences LTD at $1.60 per share on September 5, 2025.

How many Tiziana Life Sciences (TLSA) shares does the Executive Chairman now own?

After the reported purchase, Executive Chairman and Founder Gabriele Cerrone holds 43,277,143 common shares of Tiziana Life Sciences LTD.

What percentage of Tiziana Life Sciences’ issued share capital does the Executive Chairman hold?

Following the transaction, Gabriele Cerrone’s holding represents 36.28% of Tiziana Life Sciences LTD’s issued share capital.

What is the significance of this Tiziana Life Sciences Form 6-K for investors?

The report shows an insider share purchase by the Executive Chairman at $1.60 per share and confirms his substantial ownership of 36.28% of the company’s issued share capital.

Does this Tiziana Life Sciences (TLSA) Form 6-K include a press release?

Yes. The document lists as Exhibit 99.1 a Tiziana Life Sciences LTD press release dated September 5, 2025, related to the disclosed transaction.